21/04/2017 18:18:00

Statement re Exercise of Investment Manager Options

Related content
30 Nov - 
Statement re: Monthly Factsheet
08 Nov - 
Statement re Dividend Information
08 Nov - 
Notification of a tender offer

Tetragon Financial Group Ltd - Statement re Exercise of Investment Manager Options

PR Newswire

Tetragon Financial Group Limited Exercise of Investment Manager Options

LONDON, April 21, 2017 -- On 21 April 2017, Tetragon's investment manager exercised the 12,545,330 options it received from Tetragon in recognition of the work it performed in successfully arranging Tetragon's 2007 global offering and the associated raising of new capital.  The exercise price per share for the options was set at Tetragon's IPO offer price of $10.00.  As previously indicated, these options were to be settled by Tetragon on a cashless basis, and the investment manager is to receive 2,382,395 non-voting shares – the net shares resulting from the exercise of the options based on a price of $12.3442 per non-voting share.  Following the settlement of the options and as at 31 March 2017, Tetragon will have approximately 97.4 million fully-diluted non-voting shares outstanding, as compared to 97.0 million shares as at 28 February 2017.

About Tetragon:

Tetragon is a closed-ended investment company that invests in a broad range of assets, including bank loans, real estate, equities, credit, convertible bonds and infrastructure and TFG Asset Management, a diversified alternative asset management business. Where sensible, through TFG Asset Management, Tetragon seeks to own all, or a portion, of asset management companies with which it invests in order to enhance the returns achieved on its capital. Tetragon's investment objective is to generate distributable income and capital appreciation. It aims to provide stable returns to investors across various credit, equity, interest rate, inflation and real estate cycles. The company is traded on Euronext in Amsterdam N.V. and on the Specialist Fund Segment of the main market of the London Stock Exchange. For more information please visit the company's website at http://www.tetragoninv.com/.

Tetragon:

Yuko Thomas

Investor Relations

ir@tetragoninv.com

Press Inquiries:

Prosek Partners

Andy Merrill and Ryan FitzGibbon

+1 212 279 3115 ext. 216 and ext. 234

Pro-tetragon@prosek.com

This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in the United States or to conduct a public offer of securities in the United States. In addition, Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940, and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets under Section 1:107 of the Financial Markets Supervision Act as a collective investment scheme from a designated country.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

11/12/2017 10:25:28
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting
2
Algeco Scotsman Announces Debt Package for Refinancing, Acquisition of Touax Solutions Modulaires SAS and Exercise of Put Option
3
Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting
4
Exclusive: Today, 9 December 2017, Artprice confirms that the acquisition of Da Vinci's Salvator Mundi involved geopolitical mediation, and that the Vatican Museums did indeed study the offer
5
Algeco Scotsman Announces Debt Package for Refinancing, Acquisition of Touax Solutions Modulaires SAS and Exercise of Put Option

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
11 December 2017 20:58:47
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171124.1 - EUROWEB5 - 2017-12-11 21:58:47 - 2017-12-11 20:58:47 - 1000 - Website: OKAY